TECHNE CORPORATION (NASDAQ:TECH) Files An 8-K Financial Statements and Exhibits

TECHNE CORPORATION (NASDAQ:TECH) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

99.1      Press Release, dated May 2, 2017, announcing results of operations.

  

99.2      Press Release, dated May 2, 2017, announcing a cash dividend.

 

 
 
 

 

 


About TECHNE CORPORATION (NASDAQ:TECH)

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

TECHNE CORPORATION (NASDAQ:TECH) Recent Trading Information

TECHNE CORPORATION (NASDAQ:TECH) closed its last trading session up +0.50 at 107.58 with 242,558 shares trading hands.

An ad to help with our costs